Leadership
David Cheresh, PhD
Scientific Founder & Director
UCSD Pathology Vice Chair. Developed Unituxin (FDA 2015). TargeGen founder (Fedratinib FDA 2019, $7B exit). 26 issued patents.
Stephen J. McCormack, PhD
CEO & Co-Founder
Veteran biotech operator. Built MannKind ($2B), CytomX ($1.5B), AlleCure (ALK exit), NeuroSystec, Pixium Vision (now Science Corp).
Sara Weis, PhD
VP of Research & Co-Founder
Drives discovery, translational biology, and the Fibrozumab IND-enabling research roadmap.
Kamal Egodage, PhD
Chief Manufacturing Officer
Leads CMC, biologics process development, scale-up and clinical supply for Fibrozumab.
Alfred Atallah, Esq.
General Counsel
Heads corporate, IP, and transactional matters supporting financing, patents, and partnerships.
Doug Frankel
Chief People Officer
Responsible for workforce strategy, recruiting and retaining talent and shaping company.
Advisory Board
Michael Karin, PhD
UCSD / NAS member
Tumor inflammation, fibrosis biology.
Andrew Lowy, MD
UCSD Surgical Oncology
Head of Surgical Oncology, PDAC clinical trials.
Sandip Patel, MD
UCSD Clinical Trials
Clinical Trial Director, lung cancer immune therapy.
Dan Von Hoff, MD
Mayo Clinic, Arizona
World renown Pancreas Cancer physician scientist.
David Brenner, MD
Sanford Burnham Prebys CEO
Liver fibrosis & clinical trials.
David Cheresh, PhD
UCSD Research
Scientific founder — angiogenesis, integrins.